- Rovi has agreed to acquire Bristol Myers Squibb’s drug manufacturing facility in Phoenix, Arizona.
- A five-year Toll Manufacturing Agreement with BMS guarantees a minimum of $50 million per year.
Rovi announced that its subsidiary, ROIS Phoenix Inc., has entered into an Asset Purchase Agreement with Bristol Myers Squibb (BMS) for the acquisition of a drug manufacturing facility in Phoenix, Arizona. The deal includes related assets and liabilities.
As part of the transaction, Rovi has signed a Toll Manufacturing Agreement with BMS. This contract sets out conditions for continued product manufacturing at the facility. It has an initial five-year term from closing and guarantees a minimum annual payment of 50 million dollars.
The purchase price of the facility was not considered material for Rovi. The agreement remains subject to standard closing conditions.
Completion of the transaction is expected in the first half of 2026.
